You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 140 No. 4, April 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  EDITORIALS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Vapors, Viruses, and Views

Ribavirin and Respiratory Syncytial Virus

CAROLINE B. HALL, MD; JOHN T. McBRIDE, MD

Am J Dis Child. 1986;140(4):331-332.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The recent population explosion in anti-infectives seems to be almost entirely from antibacterial agents. Among the more meager nursery of antiviral agents is one that has recently been approved by the Food and Drug Administration (FDA) for respiratory syncytial virus (RSV). Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a synthetic nucleoside analogue that may be heralding a new type of battle against the common respiratory ills of childhood.

Ribavirin is of a different lineage; in vitro and in vivo it possesses inhibitory activity toward a wide range of both RNA and DNA viruses.1,2 For respiratory infections in humans it appears to be most effective when administered as an aerosol, and toxic reactions have not been observed.

Ribavirin bears a noticeable familial resemblance to guanosine and inosine. The mechanism by which it exerts its viral exorcism remains partially occult, but it does appear to specifically restrict the synthesis of viral proteins, in part by . . . [Full Text PDF of this Article]


Author Affiliations

Infectious Diseases Division; Pulmonary Division Department of Pediatrics University of Rochester Medical Center 601 Elmwood Ave Rochester, NY 14642

From the Infectious Diseases (Dr Hall) and Pulmonary (Dr McBride) Divisions, Department of Pediatrics, University of Rochester (NY) Medical Center.


Footnotes

Accepted for publication Nov 27, 1985.

Reprint requests to Department of Pediatrics, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642 (Dr Hall).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.